IOVA Q2 2025 Earnings — Iovance Biotherapeutics, Inc. Revenue & Financial Results | Market Cap Arena

IOVAIovance Biotherapeutics, Inc.

$2B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$60M+92.7% YoY

Gross Profit

$3M5.5% margin

Operating Income

-$114M-189.8% margin

Net Income

-$112M-186.2% margin

EPS (Diluted)

$-0.33

QoQ Revenue Growth

+21.5%

Cash Flow

Operating Cash Flow

-$67M

Free Cash Flow

-$75M

Stock-Based Comp.

$15M

Balance Sheet

Total Assets

$907M

Total Liabilities

$209M

Stockholders' Equity

$698M

Cash & Equivalents

$132M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$60M	$31M	+92.7%
Gross Profit	$3M	-$262,000	+1355.0%
Operating Income	-$114M	-$102M	-11.6%
Net Income	-$112M	-$97M	-15.0%

Geographic Segments

UNITED STATES

$59M98%

Non-US

$1M2%